3 results match your criteria: "UK. m.d.pickles@medschool.hull.ac.uk[Affiliation]"
Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.
Magn Reson Imaging
September 2006
Centre for Magnetic Resonance Investigations, Division of Cancer, Postgraduate Medical School, University of Hull, HU3 2JZ Hull, UK.
Traditionally, tumor response has been assessed via tumor size measurements during the course of a treatment. However, changes in these morphologically based measures occur relatively late in the course of a treatment. Alternative biomarkers are currently being evaluated to enable an earlier assessment of treatment to facilitate early cessation and cost savings.
View Article and Find Full Text PDFDiffusion-weighted imaging of normal and malignant prostate tissue at 3.0T.
J Magn Reson Imaging
February 2006
Centre for Magnetic Resonance Investigations, Division of Cancer, Postgraduate Medical School, University of Hull, Hull, UK.
Purpose: To measure the apparent diffusion coefficient (ADC) of normal and malignant prostate tissue at 3.0T using a phased-array coil and parallel imaging, and determine the utility of ADC values in differentiating tumor from normal peripheral zone (PZ).
Materials And Methods: ADC values were calculated for 49 patients (tumor and PZ) with evidence of prostate cancer.
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
Breast Cancer Res Treat
May 2005
Post-graduate Medical School, Division of Cancer, Centre for Magnetic Resonance Investigations, University of Hull, UK.
Article Synopsis
- Neoadjuvant chemotherapy is the standard treatment for locally advanced breast cancer, but identifying early responders versus non-responders remains a challenge.
- A study involving 68 patients used pharmacokinetically modelled dynamic contrast-enhanced MRI to assess treatment response, finding significant differences in tumor volume changes and MRI parameters between responders and non-responders.
- Results indicated that early treatment differences in kinetic parameters (Ktrans and Kep) could effectively predict responses, highlighting the potential of MRI as a monitoring tool for treatment effectiveness.